New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

In a recent regulatory review, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard ...

Premier Doug Ford called the expansion of Eisai Inc. in Mississauga “a major milestone in strengthening our plan to build ...

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages. | In a quarterly update, the FDA said it’s evaluating the need for ...

Clinical Data Studio has supported 465 global studies since its launch in 2024, reducing data review cycles by up to 80% and ...

Eisai has a long history of developing drug therapies for dementia, starting with the cholinesterase inhibitor Aricept (donepezil) which was approved for Alzheimer's disease in the 1990s and ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

INmune Bio's Alzheimer's drug XPro showed targeted benefits in patients with brain inflammation, but misses the main trial ...

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...

INmune Bio’s stock plunged by more than 50% after its TNF inhibitor failed to demonstrate efficacy in Alzheimer’s patients ...

Diagnosing Alzheimer’s is difficult, and precise biomarkers are needed to assist physicians in making accurate assessments, ...

Digging into a prespecified analysis for the mid-stage study, INmune Bio identified some clinical and biological benefits of ...